Literature DB >> 26050622

Context-dependent actions of Polycomb repressors in cancer.

M Koppens1, M van Lohuizen1,2.   

Abstract

Polycomb Group (PcG) proteins form Polycomb Repressive Complexes (PRCs) that function as epigenetic repressors of gene expression. The large variety of PcG proteins, in addition to the high number of paralogs, allows for the formation of diverse PRCs with different properties, providing fine-tuned control over cell specification. Initially identified as being oncogenes, a small number of PcG genes are involved in tumor development in part through the repression of the CDKN2A locus. Therefore, enhanced PcG-mediated repression has long been assumed to be cancer promoting. However, recent data have revealed that for some cancers, PcG proteins act as tumor suppressors, indicating that this traditional view is oversimplified. In this review, we present an overview of the roles of PcG genes in oncogenesis and how the nature of their role is context dependent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26050622     DOI: 10.1038/onc.2015.195

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  194 in total

1.  Dense chromatin activates Polycomb repressive complex 2 to regulate H3 lysine 27 methylation.

Authors:  Wen Yuan; Tong Wu; Hang Fu; Chao Dai; Hui Wu; Nan Liu; Xiang Li; Mo Xu; Zhuqiang Zhang; Tianhui Niu; Zhifu Han; Jijie Chai; Xianghong Jasmine Zhou; Shaorong Gao; Bing Zhu
Journal:  Science       Date:  2012-08-24       Impact factor: 47.728

2.  Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer.

Authors:  Wenjie Song; Kaishan Tao; Haimin Li; Chen Jin; Zhenshun Song; Jun Li; Hai Shi; Xiao Li; Zheng Dang; Kefeng Dou
Journal:  Cancer Sci       Date:  2010-03-24       Impact factor: 6.716

3.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

4.  Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein.

Authors:  Gelsomina Mansueto; Floriana Forzati; Angelo Ferraro; Pierlorenzo Pallante; Mimma Bianco; Francesco Esposito; Antonino Iaccarino; Giancarlo Troncone; Alfredo Fusco
Journal:  Genes Cancer       Date:  2010-03

5.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

6.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Authors:  Wendy Béguelin; Relja Popovic; Matt Teater; Yanwen Jiang; Karen L Bunting; Monica Rosen; Hao Shen; Shao Ning Yang; Ling Wang; Teresa Ezponda; Eva Martinez-Garcia; Haikuo Zhang; Yupeng Zheng; Sharad K Verma; Michael T McCabe; Heidi M Ott; Glenn S Van Aller; Ryan G Kruger; Yan Liu; Charles F McHugh; David W Scott; Young Rock Chung; Neil Kelleher; Rita Shaknovich; Caretha L Creasy; Randy D Gascoyne; Kwok-Kin Wong; Leandro Cerchietti; Ross L Levine; Omar Abdel-Wahab; Jonathan D Licht; Olivier Elemento; Ari M Melnick
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

7.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

8.  The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

Authors:  Mohamad Mohty; Agnes S M Yong; Richard M Szydlo; Jane F Apperley; Junia V Melo
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

10.  Polycomb CBX7 has a unifying role in cellular lifespan.

Authors:  Jesús Gil; David Bernard; Dolores Martínez; David Beach
Journal:  Nat Cell Biol       Date:  2003-11-30       Impact factor: 28.213

View more
  43 in total

1.  PTE, a novel module to target Polycomb Repressive Complex 1 to the human cyclin D2 (CCND2) oncogene.

Authors:  Sarina R Cameron; Soumyadeep Nandi; Tatyana G Kahn; Juan I Barrasa; Per Stenberg; Yuri B Schwartz
Journal:  J Biol Chem       Date:  2018-08-01       Impact factor: 5.157

Review 2.  Mechanisms of Nucleosome Dynamics In Vivo.

Authors:  Steven Henikoff
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

3.  MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

Authors:  Masaaki Yamamoto; Caining Jin; Tsuyoshi Hata; Yota Yasumizu; Yan Zhang; Deli Hong; Takahiro Maeda; Masaaki Miyo; Masayuki Hiraki; Yozo Suzuki; Kunihiko Hinohara; Hasan Rajabi; Donald Kufe
Journal:  Cancer Res       Date:  2019-03-01       Impact factor: 12.701

Review 4.  Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?

Authors:  Ewa M Michalak; Jane E Visvader
Journal:  Mol Oncol       Date:  2016-09-23       Impact factor: 6.603

5.  PRC1 Fine-tunes Gene Repression and Activation to Safeguard Skin Development and Stem Cell Specification.

Authors:  Idan Cohen; Dejian Zhao; Carmit Bar; Victor J Valdes; Katherine L Dauber-Decker; Minh Binh Nguyen; Manabu Nakayama; Michael Rendl; Wendy A Bickmore; Haruhiko Koseki; Deyou Zheng; Elena Ezhkova
Journal:  Cell Stem Cell       Date:  2018-05-03       Impact factor: 24.633

Review 6.  MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Authors:  Hasan Rajabi; Masayuki Hiraki; Donald Kufe
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

Review 7.  Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.

Authors:  Itys Comet; Eva M Riising; Benjamin Leblanc; Kristian Helin
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

8.  EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis.

Authors:  Xiaowen Guan; Houliang Deng; Un Lam Choi; Zhengfeng Li; Yiqi Yang; Jianming Zeng; Yunze Liu; Xuanjun Zhang; Gang Li
Journal:  Oncogene       Date:  2020-10-02       Impact factor: 9.867

9.  Optimization of Ligands Using Focused DNA-Encoded Libraries To Develop a Selective, Cell-Permeable CBX8 Chromodomain Inhibitor.

Authors:  Sijie Wang; Kyle E Denton; Kathryn F Hobbs; Tyler Weaver; James M B McFarlane; Katelyn E Connelly; Michael C Gignac; Natalia Milosevich; Fraser Hof; Irina Paci; Catherine A Musselman; Emily C Dykhuizen; Casey J Krusemark
Journal:  ACS Chem Biol       Date:  2019-12-12       Impact factor: 5.100

10.  Polycomb and lung cancer: When the dosage makes the (kind of) poison.

Authors:  Gaetano Gargiulo; Elisabetta Citterio; Michela Serresi
Journal:  Mol Cell Oncol       Date:  2016-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.